// App-Quantinova.ai

: Effect of DOAC Type and DOAC Dose, and Residual DOAC Level on Risk for Perioperative Major Bleeding and Arterial Thromboembolism

Researchers

Presenter

  • J. Douketis

Principal Investigators

  • A.C. Spyropoulos

  • J. Duncan

  • N. Li

  • D.M. Arnold

  • J.A. Caprini

  • K.A. Moffat

  • S. Syed

  • S. Schulman

Medical Centers

  • McMaster University, Internal Medicine, Hamilton, Canada

  • The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Department of Medicine, New York, United States

  • NorthShore University Health System, Evanston, Illinois, United States

  • Hamilton Regional Laboratory Medicine Program, McMaster University, Hamilton, ON, Canada

  • McMaster University, Department of Surgery, Hamilton, ON, Canada

  • The First I.M. Sechenov Moscow State Medical, Moscow, Russian Federation

Locations

  • Canada

  • United States

  • Russia

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • rivaroxaban

  • Pradax

  • apixaban

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved